Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Microbiol. 2012;2012:386410. doi: 10.1155/2012/386410. Epub 2011 Nov 30.

Development of Class IIa Bacteriocins as Therapeutic Agents.

Author information

  • 1Department of Chemistry, University of Alberta, Edmonton, AB, Canada T6G 2G2.

Abstract

Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. Therefore, the therapeutic development of these bacteriocins will be reviewed. Biological and chemical modifications to both stabilize and increase the potency of bacteriocins are discussed, as well as the optimization of their production and purification. The suitability of bacteriocins as pharmaceuticals is explored through determinations of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in mouse models. Recent results suggest that class IIa bacteriocins show promise as a class of therapeutic agents.

PMID:
22187559
PMCID:
PMC3236453
DOI:
10.1155/2012/386410
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center